IGF-1 LR3 Side Effects and Safety
Reported IGF-1 LR3 side effects, contraindications, and safety signals.
Safety & Contraindications
IGF-1 LR3 is a research compound and is not FDA-approved for general use. It should be avoided by anyone with active malignancy, pregnancy, and hypoglycemia risk. Most reported effects are mild and dose-dependent, so start at the low end of the dosing range and titrate up slowly rather than chasing a maximal dose. Injection-site redness, itching, or a temporary lump are the most common local reactions; rotate sites and use clean technique to keep them minimal.
What to Monitor
Track IGF-1, HbA1c, fasting glucose, and fasting insulin while you're running IGF-1 LR3 so you can catch any drift early and adjust before it becomes a problem. Add these to your REGEN biomarker dashboard and re-check on your normal cadence.
Contraindications
- active malignancy
- pregnancy
- hypoglycemia risk
References
- Insulin-like growth factor I and muscle growth · Adams GR · 2002
- Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. · Engel MG, Narayan S, Cui MH et al. · 2025
- Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical ... · Bailes J, Soloviev M · 2021
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. · White A, Stremming J, Wesolowski SR et al. · 2025
- IGF-1 Has Plaque-Stabilizing Effects in Atherosclerosis by Altering ... · von der Thüsen JH, Borensztajn KS, Moimas S, van Heiningen S, Teeling P, van Berkel TJ, Biessen EA · 2011
- Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration. · Yavuz E, Sağır MS, Ercan A et al. · 2025